Sorcin a Potential Molecular Target for Cancer Therapy.
Sorcin a Potential Molecular Target for Cancer Therapy. Transl Oncol. 2018 Sep 11;11(6):1379-1389 Authors: Shabnam B, Padmavathi G, Banik K, Girisa S, Monisha J, Sethi G, Fan L, Wang L, Mao X, Kunnumakkara AB Abstract Sorcin (Soluble resistance related calcium binding protein) is a small soluble penta EF family (PEF) of calcium (Ca2+) binding protein (22,000 Da). It has been reported to play crucial roles in the regulation of calcium homeostasis, apoptosis, vesicle trafficking, cancer development, and multidrug resistance (MDR). Overexpression of sorcin has been reported to be associated with different cancers such as breast cancer, colorectal cancer, gastric cancer, leukemia, lung cancer, nasopharyngeal cancer, ovarian cancer, etc. Essentially, expression of sorcin has been found to be elevated in cancer cells as compared to normal cells, indicating that it has prominent role in cancer. Moreover, sorcin was found to be the regulator of various proteins that has an association with carcinogenesis including NF-κB, STAT3, Akt, ERK1/2, VEGF, MMPs, caspases, etc. Sorcin was also found to regulate apoptosis, as silencing of the same resulted in increased levels of proapoptotic genes and induced mitochondrial apoptotic pathway in cancer. Interestingly, mutations in the sorcin gene have been closely linked with poor overall survival in bladder cancer, brain lower-grade glioma, glioblastoma, glioblastoma multiforme, kidney renal clear cell carcinoma, and s...
Publication date: Available online 19 September 2020Source: European Journal of Surgical OncologyAuthor(s): Robert A. Nagourney, Steven Evans, Peter H. Tran, Adam J. Nagourney, Paul H. Sugarbaker
Publication date: Available online 19 September 2020Source: European Journal of Surgical OncologyAuthor(s): Loek A.W. de Jong, Nielka P. van Erp, Philip R. de Reuver
Publication date: Available online 19 September 2020Source: European Journal of Surgical OncologyAuthor(s): W.J. Koemans, J.W. van Sandick, A.D.R. Huitema
Authors: Teng M, Zhou S, Cai C, Lupien M, He HH Abstract Prostate cancer is the most commonly diagnosed non-cutaneous cancers in North American men. While androgen deprivation has remained as the cornerstone of prostate cancer treatment, resistance ensues leading to lethal disease. Forkhead box A1 (FOXA1) encodes a pioneer factor that induces open chromatin conformation to allow the binding of other transcription factors. Through direct interactions with the Androgen Receptor (AR), FOXA1 helps to shape AR signaling that drives the growth and survival of normal prostate and prostate cancer cells. FOXA1 also possesse...
Publication date: Available online 19 September 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Iris van ’t Erve, Marjolein J.E. Greuter, Karen Bolhuis, Daan C.L. Vessies, Alessandro Leal, Geraldine R. Vink, Daan van den Broek, Victor E. Velculescu, Cornelis J.A. Punt, Gerrit A. Meijer, Veerle M.H. Coupé, Remond J.A. Fijneman
Publication date: Available online 19 September 2020Source: Pathology - Research and PracticeAuthor(s): Nazila Fathi Maroufi, Nima Ashouri, Zohreh Mortezania, Zahra Ashoori, Vahid Vahedian, Mohammad Taher Amirzadeh-Iranaq, Amir Fattahi, Hamid Kazemzadeh, Mariano Bizzarri, Maryam Akbarzadeh, Hamid Reza Nejabati, Yousef Faridvand, Mohammad-Reza Rashidi, Mohammad Nouri
Publication date: September 2020Source: Human Pathology: Case Reports, Volume 21Author(s): Yuri Noda, Yuko Nakanishi, Ayaka Izui, Hiroyo Takahashi, Chiya Oshiro, Hideo Inaji, Masaru Yamasaki
Conclusion: A nisin-producing probiotic, can be used to treat 'disease-altered' biofilms and promote healthier oral biofilms, which may be useful for improving patient oral health. PMID: 32944159 [PubMed]
Conclusions: Although morphological and biochemical tests are still used, they are associated with high-throughput sequencing techniques, due to their accuracy and time saving for profiling the predominant species in oral mycobiome. PMID: 32944157 [PubMed]
In this study, 73 patients (49.3%) had osteopenia and 28 patients (18.9%) were osteoporotic. BMI was significantly lower in the osteoporosis group compared with the normal group (P
More News: Adenocarcinoma | Bladder Cancer | Brain | Brain Cancers | Brain Tumor | Breast Cancer | Breast Carcinoma | Calcium | Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Clear Cell Carcinoma | Colorectal Cancer | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Glioma | Leukemia | Lung Cancer | Multidrug Resistance | Nasopharyngeal Cancer | Neurology | Ovarian Cancer | Ovaries | Urology & Nephrology